Free Trial

Alvotech (ALVO) Competitors

Alvotech logo
$10.14 -0.23 (-2.23%)
As of 10:51 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ALVO vs. SMMT, RDY, ASND, MRNA, VTRS, QGEN, BPMC, ROIV, RVMD, and VRNA

Should you be buying Alvotech stock or one of its competitors? The main competitors of Alvotech include Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Revolution Medicines (RVMD), and Verona Pharma (VRNA). These companies are all part of the "pharmaceutical products" industry.

Alvotech vs.

Summit Therapeutics (NASDAQ:SMMT) and Alvotech (NASDAQ:ALVO) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, community ranking, media sentiment, risk and dividends.

Summit Therapeutics received 307 more outperform votes than Alvotech when rated by MarketBeat users. Likewise, 58.58% of users gave Summit Therapeutics an outperform vote while only 50.00% of users gave Alvotech an outperform vote.

CompanyUnderperformOutperform
Summit TherapeuticsOutperform Votes
314
58.58%
Underperform Votes
222
41.42%
AlvotechOutperform Votes
7
50.00%
Underperform Votes
7
50.00%

Summit Therapeutics currently has a consensus target price of $37.40, suggesting a potential upside of 69.38%. Alvotech has a consensus target price of $18.00, suggesting a potential upside of 73.58%. Given Alvotech's higher probable upside, analysts plainly believe Alvotech is more favorable than Summit Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Summit Therapeutics
0 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
3.09
Alvotech
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

4.6% of Summit Therapeutics shares are owned by institutional investors. 84.9% of Summit Therapeutics shares are owned by company insiders. Comparatively, 0.5% of Alvotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Alvotech had 7 more articles in the media than Summit Therapeutics. MarketBeat recorded 23 mentions for Alvotech and 16 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.38 beat Alvotech's score of 0.18 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Summit Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
9 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Alvotech
2 Very Positive mention(s)
5 Positive mention(s)
12 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summit Therapeutics has a net margin of 0.00% compared to Alvotech's net margin of -123.47%. Alvotech's return on equity of 0.00% beat Summit Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Summit TherapeuticsN/A -85.42% -52.66%
Alvotech -123.47%N/A -35.87%

Summit Therapeutics has a beta of -1.06, indicating that its stock price is 206% less volatile than the S&P 500. Comparatively, Alvotech has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500.

Alvotech has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Summit Therapeutics$700K23,425.81-$614.93M-$0.34-64.94
Alvotech$585.60M5.34-$551.73M$0.3728.03

Summary

Summit Therapeutics beats Alvotech on 10 of the 19 factors compared between the two stocks.

Get Alvotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALVO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALVO vs. The Competition

MetricAlvotechBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$3.13B$3.10B$5.57B$8.67B
Dividend YieldN/A1.59%5.27%4.19%
P/E Ratio-5.6133.8227.2020.17
Price / Sales5.34476.37412.92161.94
Price / CashN/A168.6838.2534.64
Price / BookN/A3.497.114.72
Net Income-$551.73M-$72.35M$3.23B$247.80M
7 Day Performance-4.25%9.39%3.77%2.76%
1 Month Performance7.13%24.23%13.33%9.71%
1 Year Performance-27.94%-16.25%32.02%14.51%

Alvotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALVO
Alvotech
2.1862 of 5 stars
$10.14
-2.2%
$18.00
+77.5%
-28.3%$3.06B$585.60M-5.484
SMMT
Summit Therapeutics
2.9993 of 5 stars
$17.73
-2.7%
$37.40
+110.9%
+176.7%$13.17B$700,000.00-63.32110Analyst Forecast
Analyst Revision
Gap Up
High Trading Volume
RDY
Dr. Reddy's Laboratories
1.1953 of 5 stars
$14.73
+0.0%
$17.00
+15.4%
+9.5%$12.29B$325.54B23.4524,800
ASND
Ascendis Pharma A/S
3.2589 of 5 stars
$175.69
+7.9%
$216.07
+23.0%
+31.1%$10.71B$368.70M-24.75640Positive News
Analyst Forecast
Analyst Revision
MRNA
Moderna
4.418 of 5 stars
$27.05
+1.8%
$53.58
+98.1%
-81.4%$10.46B$3.14B-2.913,900Trending News
VTRS
Viatris
2.1627 of 5 stars
$8.69
-1.1%
$10.50
+20.8%
-14.0%$10.20B$14.33B-11.7437,000
QGEN
Qiagen
3.1324 of 5 stars
$44.89
-0.5%
$48.42
+7.9%
+6.0%$9.98B$2.00B125.006,030
BPMC
Blueprint Medicines
0.8531 of 5 stars
$127.79
+26.1%
$125.69
-1.6%
+23.0%$8.25B$562.12M-118.32640High Trading Volume
ROIV
Roivant Sciences
2.3295 of 5 stars
$11.17
+1.6%
$17.50
+56.7%
+7.5%$7.97B$29.05M-74.46860
RVMD
Revolution Medicines
4.1708 of 5 stars
$40.65
+3.2%
$67.08
+65.0%
+5.3%$7.57B$742,000.00-11.32250
VRNA
Verona Pharma
1.7043 of 5 stars
$84.10
+3.6%
$82.13
-2.3%
+586.0%$6.82B$118.54M-43.8030Positive News
Analyst Forecast
Analyst Revision

Related Companies and Tools


This page (NASDAQ:ALVO) was last updated on 6/11/2025 by MarketBeat.com Staff
From Our Partners